The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations
L Jondreville, D Krzisch, E Chapiro… - American Journal of …, 2020 - Wiley Online Library
Chromosomal abnormalities are frequently observed in patients with chronic lymphocytic
leukemia (CLL) and have prognostic value. Deletions of the short arm of chromosome 17 …
leukemia (CLL) and have prognostic value. Deletions of the short arm of chromosome 17 …
[HTML][HTML] From biology to treatment of monoclonal gammopathies of neurological significance
Simple Summary The peripheral nervous systems may be involved by several
hematological diseases ranging from preneoplastic diseases to overt malignancies or …
hematological diseases ranging from preneoplastic diseases to overt malignancies or …
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
M Fürstenau, YJ Thus, S Robrecht, CHM Mellink… - Blood, 2023 - ashpublications.org
Complex karyotypes have been associated with inferior outcomes in chronic lymphocytic
leukemia (CLL) treated with chemoimmunotherapy (CIT), whereas their prognostic impact in …
leukemia (CLL) treated with chemoimmunotherapy (CIT), whereas their prognostic impact in …
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib
AS Kittai, C Miller, D Goldstein, Y Huang… - Blood, The Journal …, 2021 - ashpublications.org
Complex karyotype, defined as≥ 3 cytogenetic abnormalities, is prognostic of survival in
patients treated with ibrutinib or venetoclax in relapsed/refractory (RR) chronic lymphocytic …
patients treated with ibrutinib or venetoclax in relapsed/refractory (RR) chronic lymphocytic …
[HTML][HTML] The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation
A Visentin, L Bonaldi, GM Rigolin, FR Mauro… - …, 2022 - ncbi.nlm.nih.gov
Complex karyotype (CK) at chronic lymphocytic leukemia (CLL) diagnosis is a negative
biomarker of adverse outcome. Since the impact of CK and its subtypes, namely type-2 CK …
biomarker of adverse outcome. Since the impact of CK and its subtypes, namely type-2 CK …
[HTML][HTML] Time to next treatment as a meaningful endpoint for trials of primary cutaneous lymphoma
BA Campbell, JJ Scarisbrick, YH Kim, RA Wilcox… - Cancers, 2020 - mdpi.com
Time to next treatment (TTNT) is an emerging endpoint in clinical studies of primary
cutaneous T-cell lymphomas (CTCL), with utility as a surrogate marker for the “duration of …
cutaneous T-cell lymphomas (CTCL), with utility as a surrogate marker for the “duration of …
[HTML][HTML] In chronic lymphocytic leukemia the JAK2/STAT3 pathway is constitutively activated and its inhibition leads to CLL cell death unaffected by the protective bone …
The bone marrow microenvironment promotes proliferation and drug resistance in chronic
lymphocytic leukemia (CLL). Although ibrutinib is active in CLL, it is rarely able to clear …
lymphocytic leukemia (CLL). Although ibrutinib is active in CLL, it is rarely able to clear …
[HTML][HTML] Optical genome mapping as an alternative to FISH-based cytogenetic assessment in chronic lymphocytic leukemia
A Valkama, S Vorimo, TA Kumpula, H Räsänen… - Cancers, 2023 - mdpi.com
Simple Summary In many countries, the standard-of-care cytogenetic analysis of chronic
lymphocytic leukemia (CLL) is based on the fluorescence in situ hybridization (FISH) …
lymphocytic leukemia (CLL) is based on the fluorescence in situ hybridization (FISH) …
[HTML][HTML] Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia
G Boncompagni, V Tatangelo, L Lopresti… - Cell Death & …, 2024 - nature.com
The tumor microenvironment (TME) plays a central role in the pathogenesis of chronic
lymphocytic leukemia (CLL), contributing to disease progression and chemoresistance …
lymphocytic leukemia (CLL), contributing to disease progression and chemoresistance …
[HTML][HTML] Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: a real-life CLL …
A Visentin, FR Mauro, G Catania, A Fresa… - Frontiers in …, 2022 - frontiersin.org
One of the main issues in the treatment of patients with chronic lymphocytic leukemia (CLL)
deals with the choice between continuous or fixed-duration therapy. Continuous ibrutinib …
deals with the choice between continuous or fixed-duration therapy. Continuous ibrutinib …